PRODUCT

We are specialized in developing small molecules therapeutics for cancer.

​

The lead drug in our pipeline is a dual inhibitor small molecule that prevents growth and metastasis of the cancer cells. The drug is called Metavert.

Metavert is an anti-cancer drug developed by Avenzoar.

Metavert is a small molecular dual inhibitor that targets two pro-cancer pathways at the same time. Pre-clinical results show strong prevention of pancreatic cancer growth and metastasis with no significant toxicity.

Metavert will be tested in pancreatic cancer patients in late 2019. Lung and liver cancer patients will be considered for clinical trials as the pre-clinical results show that Metavert affects lung and liver cancer cells.